Skip to main content
Isofol Medical logo

Isofol Medical — Investor Relations & Filings

Ticker · ISOFOL ISIN · SE0009581051 LEI · 549300MCXYAHG7VBHX75 ST Professional, scientific and technical activities
Open in API
Filings indexed 208 across all filing types
Latest filing 2023-12-28 Regulatory Filings
Country SE Sweden
Listing ST ISOFOL

About Isofol Medical

https://isofolmedical.com/

Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.

Recent filings

Filing Released Lang Actions
Isofol presenterar ytterligare resultat från laboratorietester med arfolitixorin som visar tilläggseffekter
Regulatory Filings Classification · 95% confidence The document is a press release dated December 28, 2023, announcing laboratory test results for the drug candidate arfolitixorin, specifically mentioning 'intressanta tilläggseffekter' (interesting additional effects) and plans for further bioinformatic analysis and potential clinical development. It is an update on ongoing research and development activities, not a formal financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). Since it is an announcement providing specific, non-financial operational/R&D updates that don't fit the other specific categories (like LTR for legal or CAP for financing), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements not covered elsewhere, especially when the content is operational/scientific news.
2023-12-28 Swedish
Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects
Regulatory Filings Classification · 95% confidence The document is a press release dated December 28, 2023, announcing 'additional results from laboratory tests with arfolitixorin showing supplementary effects' related to colorectal cancer treatment. It discusses ongoing scientific evaluation and future plans for clinical development. This type of announcement, detailing scientific progress or preliminary results outside of a formal financial report (like 10-K or IR), often falls under general investor relations communication. Since it is not a formal Earnings Release (ER), Interim Report (IR), or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Update (CAP), and it is not a transcript (CT) or a presentation (IP), the most appropriate category is the general 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard corporate updates, or potentially 'LTR' if the results were related to regulatory feedback, but RNS is safer for general scientific updates released via press release. Given the context of providing updates on drug development progress, it is a significant corporate announcement that doesn't fit the other specific categories well. It is not a Report Publication Announcement (RPA) because it is presenting the results themselves, not just announcing the publication of a separate report. Therefore, RNS is the best fit as a general regulatory/corporate announcement.
2023-12-28 English
Isofol’s board of directors announces its position on minority shareholder's proposal ahead of extraordinary general meeting
Board/Management Information Classification · 98% confidence The document is an announcement from Isofol Medical AB regarding the board of directors' position on a proposal made by minority shareholders ahead of an extraordinary general meeting (EGM). The core content discusses the potential resignation of the entire board if a specific individual is elected, which directly relates to the composition and governance of the board of directors. This aligns best with the 'Board/Management Information' category (MANG), which covers announcements of changes in the company's board of directors or senior management. While an EGM is mentioned, the focus is on the board's reaction and potential changes, not the voting results (DVA) or the proxy materials (PSI).
2023-12-13 English
Styrelsen i Isofol meddelar sin inställning till minoritetsaktieägares förslag inför extra bolagsstämma
Board/Management Information Classification · 98% confidence The document is a press release from Isofol Medical AB dated December 13, 2023, announcing the current board members' intention to resign if a specific individual (Jan-Eric Österlund) is elected as a new director at an upcoming Extraordinary General Meeting (EGM) requested by minority shareholders. This announcement directly concerns changes in the composition of the company's governing body (the Board of Directors) due to a shareholder proposal and potential election outcome. This aligns perfectly with the definition for Board/Management Information (MANG), which covers 'Announcement of changes in the company's board of directors or senior management.' Although an EGM is mentioned, the core subject is the board's reaction/stance regarding potential new management/board composition, not the voting results (DVA) or the AGM materials themselves (AGM-R).
2023-12-13 Swedish
Director's Dealing 2023
Director's Dealing Classification · 98% confidence The document details a change in shareholding and voting rights for an issuer (Isofol Medical AB) by a holder (Avanza Bank Holding AB for Avanza Pension). It explicitly lists the quantity of shares (16,236,949) and the resulting percentage of voting rights (10.05288%) after a transaction on 08/12/2023. This structure—reporting changes in significant ownership thresholds—is characteristic of a Major Shareholding Notification. This aligns with the definition for 'Major Shareholding Notification' (MRQ). It is not an earnings release, annual report, or a general regulatory filing (RNS) because it fits a more specific category.
2023-12-11 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding, specifically a 'Sell' transaction, resulting in the holder's total voting rights percentage falling to 9.9826%. It explicitly mentions the 'Reason for major shareholding notification' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' holdings, including the number of shares and percentage. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2023-12-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.